Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 96, Issue -, Pages 110-134Publisher
ELSEVIER
DOI: 10.1016/j.addr.2015.04.019
Keywords
Maturation; Human engineered cardiac tissue; Pluripotent stem cell-derived cardiomyocytes; Drug toxicity; Target validation; Regenerative medicine
Categories
Funding
- Heart and Stoke Foundation [GIA T6946]
- Canadian Institutes of Health Research Operating Grant [MOP 126027]
- Natural Sciences and Engineering Research Council of Canada [RGPIN 326982-10]
- National Institutes of Health [2R01 HL076485]
- Canada Research Chair (Tier 2)
- Steacie Fellowship
Ask authors/readers for more resources
Engineering functional human cardiac tissue that mimics the native adult morphological and functional phenotype has been a long held objective. In the last 5 years, the field of cardiac tissue engineering has transitioned from cardiac tissues derived from various animal species to the production of the first generation of human engineered cardiac tissues (hECTs), due to recent advances in human stem cell biology. Despite this progress, the hECTs generated to date remain immature relative to the native adult myocardium. In this review, we focus on the maturation challenge in the context of hECTs, the present state of the art, and future perspectives in terms of regenerative medicine, drug discovery, preclinical safety testing and pathophysiological studies. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available